What Curis does

Curis, Inc. is a clinical-stage biotechnology company headquartered in Lexington, Massachusetts, founded in 2000 and publicly traded on NASDAQ under ticker CRIS. The company's core focus is the development of emavusertib (CA-4948), an orally available small molecule that inhibits both IRAK4 and FLT3, enabling dual blockade of NF-kB through the TLR and BCR pathways. Emavusertib is being evaluated in Phase 1/2 and Phase 2 clinical trials across hematologic malignancies including primary and secondary CNS lymphoma (TakeAim Lymphoma study), chronic lymphocytic leukemia (TakeAim CLL), and acute myeloid leukemia and myelodysplastic syndromes (TakeAim Leukemia study), with key clinical collaborations at Dana-Farber Cancer Institute, Mayo Clinic, and IRCCS Bologna. The asset has received FDA Orphan Drug Designation for PCNSL, AML, and MDS, plus European Commission Orphan Drug Designation for PCNSL. The pipeline also includes Fimepinostat (HDAC/PI3K inhibitor for MYC-altered cancers), CA-327 (TIM3/PDL1 inhibitor), and CA-170 (VISTA/PDL1 inhibitor), with emavusertib licensed exclusively from Aurigene Discovery Technologies via a 2015 collaboration.

The company's revenue model has historically been driven by royalty payments from Genentech and Roche's net sales of Erivedge (vismodegib), a hedgehog pathway inhibitor originally developed by Curis. However, in November 2025 Curis sold its Erivedge royalty interest and associated intellectual property to TPC Investments Royalty LLC for $2.5 million upfront, eliminating this revenue stream. FY2025 reported revenue was $9.4 million (down from $10.9M in FY2024), all royalty-derived and now discontinued. The company has no commercial products and does not yet generate product revenue, with commercialization dependent on regulatory approval and likely executed via pharmaceutical partnership or internal specialty oncology build-out. Operating geographies are concentrated in the United States, with clinical trial expansion into Europe. The company employs 11-50 people and is funded through repeated dilutive financings, most recently a January 2026 PIPE of up to $80.8 million led by Laidlaw & Company, extending cash runway into the second half of 2027.

Name

Curis

Legal name

Curis, Inc.

Website

https://curis.com

Company type

Public

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

Curis is a clinical-stage biotechnology company developing emavusertib (CA-4948), an IRAK4/FLT3 inhibitor in Phase 1/2 and Phase 2 trials for hematologic malignancies including PCNSL, CLL, and AML, with FDA and EMA Orphan Drug Designations and exclusive licensing from Aurigene Discovery Technologies.

Ownership category

akta.pro rank

Product category

Oncology Biopharmaceuticals

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

Keywords

• Oncology drug development
• Small molecule therapeutics
• Kinase inhibitor research
• Hematologic cancer treatments
• Clinical stage biopharmaceuticals

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Erivedge Royalties (Discontinued): Curis historically received royalty revenues from Genentech and Roche's net sales of Erivedge. On November 6, 2025, the company sold its interest in Curis Royalty LLC, including the Erivedge intellectual property and License Agreement with Genentech, to TPC Investments Royalty LLC for $2.5 million upfront consideration. Following this sale, the company is no longer entitled to revenues under the License Agreement, eliminating this revenue stream going forward.
2. Private Placement Financing: Company raised gross proceeds of up to $80.8 million through private placement financing involving Series B convertible preferred stock and warrants to fund research and development of emavusertib and general corporate expenses.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Curis is a clinical-stage biotechnology company developing orally available small molecule cancer therapeutics, with its lead candidate emavusertib (CA-4948), an IRAK4 and FLT3 inhibitor, being evaluated in Phase 1/2 and Phase 2 clinical studies for the treatment of primary CNS lymphoma (PCNSL), chronic lymphocytic leukemia (CLL), and acute myeloid leukemia (AML). The company also has pipeline candidates fimepinostat, CA-327, and CA-170 targeting other hematologic and immune checkpoint pathways. Historically, Curis generated royalty revenue from Genentech and Roche's sales of Erivedge; that royalty interest was divested to TPC Investments Royalty LLC in November 2025.

Product overview

Curis is a biotechnology company focused on the development of innovative therapeutics for cancer treatment. The company's lead product is emavusertib (CA-4948), an orally available small molecule IRAK4 and FLT3 inhibitor being evaluated in multiple clinical trials for lymphoma (TakeAim Lymphoma), chronic lymphocytic leukemia (TakeAim CLL), and acute myeloid leukemia. The pipeline also includes Fimepinostat (HDAC/PI3K inhibitor for MYC-altered cancers), CA-327 (TIM3/PDL1 inhibitor), and CA-170 (VISTA/PDL1 inhibitor). The company operates through a 2015 collaboration with Aurigene Discovery Technologies Limited for emavusertib licensing rights.

Differentiator

Problem solved

Functional benefit

Brands

• Emavusertib (CA-4948): Orally available small molecule IRAK4 and FLT3 inhibitor being developed for the treatment of hematologic malignancies including lymphoma, CLL, and AML.
• Fimepinostat
• CA-327
• CA-170

Products and services

• Emavusertib (CA-4948)

Quantifiable outcome

• 100% objective response rate (5 of 5 patients) in BTKi-naïve PCNSL patients treated with emavusertib + ibrutinib combination
• +3 more outcomes

Named customers3 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• Aurigene Discovery Technologies LimitedcoreStrategic or Co-development Partner · 1 January 20152015 collaboration providing Curis with exclusive license to emavusertib (CA-4948). This is the company's lead drug candidate and core asset. The partnership enables Curis to develop and commercialize the IRAK4 and FLT3 inhibitor for cancer treatment.
• Genentech and RocheminorStrategic or Co-development PartnerHistorically, Curis received royalty revenues from Genentech and Roche's net sales of Erivedge. This licensing arrangement ended following the sale of the royalty interest to TPC Investments Royalty LLC in November 2025.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Kura Oncology: Clinical-stage small molecule oncology company developing tipifarnib (HRAS) and KO-539 (menin inhibitor) for AML and other hematologic malignancies. Directly comparable as a micro/mid-cap biotech with a hematology-focused pipeline of single-agent and combination therapies.
• Rigel Pharmaceuticals: Commercial-stage small molecule company focused on hematologic disorders and cancers (TAVALISSE for ITP, Rezlidhia for AML, Gavreto). Comparable as a small molecule developer with both approved and clinical-stage hematology assets and a similar enterprise scale.
• Cogent Biosciences: Clinical-stage biotech developing bezuclastinib (KIT D816V inhibitor) for systemic mastocytosis and GIST. Comparable as a small-molecule precision oncology company targeting hematologic malignancies with similar enterprise size and clinical-stage profile.
• Kronos Bio: Clinical-stage oncology company developing small molecules targeting dysregulated transcription (lanifibranor in AML/MDS). Comparable as a small-cap clinical-stage biotech focused on hematologic cancer targets and combination regimens.

Emerging players

• Kymera Therapeutics: Clinical-stage biotech developing targeted protein degraders (including IRAK4 degraders) for oncology and immunology. Comparable technology overlap on IRAK4 modulation for hematologic cancers and similar small-cap clinical-stage profile.

Broad incumbents

• AstraZeneca: Major oncology company marketing Calquence (acalabrutinib BTKi) and with active IRAK4 research programs. Comparable as a broad incumbent in the BTKi/IRAK4 hematology space and a likely potential partner or acquirer for Curis.
• AbbVie: Global oncology leader marketing Imbruvica (ibrutinib) — the BTKi used in Curis's combination trials — and historically developing IRAK4 inhibitors. Comparable as a strategic partner candidate and dominant player in the BTKi/CLL landscape.
• Bristol Myers Squibb: Large oncology company with active IRAK4-targeted programs and a portfolio of hematology therapies. Comparable as a broad incumbent operating in the IRAK4/BTKi space and a potential strategic acquirer.
• Eli Lilly: Major oncology company marketing Jaypirca (pirtobrutinib), a next-generation BTKi that competes in Curis's combination setting. Comparable as a broad incumbent in the BTKi/CLL competitive landscape and a relevant benchmark for IRAK4/BTKi combination strategies.
• Pfizer: Global pharma with historical IRAK4 small molecule programs and a broad hematology/oncology portfolio. Comparable as a broad incumbent in the IRAK4 mechanistic space and a potential strategic acquirer of late-stage hematology assets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/curisinc
• LinkedInlinkedin.com/company/curis

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds12 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curis